Lionheart Health, Inc., a biotechnology company focused on bioelectric regeneration and longevity, announced the filing of a non-provisional U.S. patent covering its new platform technology: Bioelectric-Enhanced Klotho Nanoflowers for Aging Reversal and Healthspan Extension. The patent protects a therapeutic system that integrates nanoflower-format nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to target cellular and mitochondrial drivers of aging.
The platform centers on engineered “nanoflowers”—flower-shaped hybrid nanoparticles capable of upregulating Klotho, a longevity-associated protein known to improve brain, kidney, cardiovascular, and metabolic health. These nanoflowers are designed to restore mitochondrial function by enhancing ATP production and reducing oxidative stress, deliver targeted bioactive agents including peptides, plasmids, mRNA, and CRISPRa activators, act as nanozyme catalysts that reduce reactive oxygen species, and enhance regenerative signaling when activated by precise bioelectric patterns. According to the company, the nanoflowers respond to Lionheart’s proprietary bioelectric stimulation sequences, which increase cellular uptake, activate intracellular pathways, and amplify biological performance.
Howard J. Leonhardt, Founder, Lead Inventor and Chief Executive Officer of Lionheart Health, stated: “This invention represents the convergence of three of the most powerful emerging technologies in biotechnology—bioelectric signaling, nanomedicine, and Klotho modulation. Our goal is to create a system that reverses biological age at the cellular level and enhances healthspan safely, non-invasively, and affordably.” The patent filing adds to Lionheart Health’s growing intellectual property portfolio, which includes technologies for bioelectric-controlled protein expression, stem-cell mobilization, mitochondrial restoration, and regenerative aesthetic platforms.
Klotho is widely recognized as one of the most promising longevity molecules, with decreased levels associated with accelerated aging, cognitive decline, inflammation, and kidney dysfunction. Lionheart’s new platform enables targeted Klotho delivery and activation inside mitochondrial and cellular compartments responsible for aging. Dr. Leslie Miller, Chief Medical Officer and former President of the International Society for Heart and Lung Transplantation, commented: “Bioelectric-enhanced Klotho nanoflowers give us a programmable, multi-modal tool to address the root causes of aging—declining energy production, rising inflammation, and loss of regenerative capacity. This filing marks a major milestone in longevity therapeutics.”
Lionheart Health is currently preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics across the U.S. and internationally. The company plans to integrate bioelectric-enhanced Klotho nanoflowers into its XPRIZE Healthspan competition program. More information about Lionheart Health can be found at LionheartHealthStim.com, LionheartLongevity.com, and LeonhardtVentures.com.
